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Abstract
Rationale The appetite-stimulating properties of cannabis are
well documented and have been predominantly attributed to the
hyperphagic activity of the psychoactive phytocannabinoid,
Δ9-tetrahydrocannabinol (Δ9-THC). However, we have previ-
ously shown that a cannabis extract devoid of Δ9-THC still
stimulates appetite, indicating that other phytocannabinoids al-
so elicit hyperphagia. One possible candidate is the non-
psychoactive phytocannabinoid cannabigerol (CBG), which
has affinity for several molecular targets with known involve-
ment in the regulation of feeding behaviour.
Objectives The objective of the study was to assess the effects
of CBG on food intake and feeding pattern microstructure.
Methods Male Lister hooded rats were administered CBG
(30–120 mg/kg, per ora (p.o.)) or placebo and assessed in
open field, static beam and grip strength tests to determine a
neuromotor tolerability profile for this cannabinoid.
Subsequently, CBG (at 30–240 mg/kg, p.o.) or placebo was
administered to a further group of pre-satiated rats, and hourly
intake and meal pattern data were recorded over 2 h.
Results CBG produced no adverse effects on any parameter in
the neuromotor tolerability test battery. In the feeding assay,
120–240 mg/kg CBGmore than doubled total food intake and
increased the number of meals consumed, and at 240 mg/kg
reduced latency to feed. However, the sizes or durations of
individual meals were not significantly increased.
Conclusions Here, we demonstrate for the first time that CBG
elicits hyperphagia, by reducing latency to feed and increasing
meal frequency, without producing negative neuromotor side
effects. Investigation of the therapeutic potential of CBG for
conditions such as cachexia and other disorders of eating and
body weight regulation is thus warranted.
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Abbreviations
CBG Cannabigerol
CBD Cannabidiol
pCB Phytocannabinoid
eCB Endocannabinoid
Δ9-THC Δ9-tetrahydrocannabinol
CB1R Cannabinoid receptor type 1
CB2R Cannabinoid receptor type 2
AEA Arachidonoylethanolamide
2-AG 2-Arachidonoylglycerol
5-HT1AR 5-Hydroxytryptamine receptor type 1A
Introduction
Cannabis sativa L. has been utilised for medicinal and recre-
ational purposes for millennia and is increasingly being
recognised as a valuable source of unique compounds
(phytocannabinoids) with a multitude of potential therapeutic
applications (Deiana et al. 2012). The main psychoactive con-
stituent of C. sativa, Δ9-tetrahydrocannabinol (Δ9-THC), was
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first isolated and characterised in the 1960s (Mechoulam &
Gaoni 1965; Gaoni & Mechoulam 1971), and this has been
followed by the discovery of numerous additional
phytocannabinoids (pCBs) over the last two decades (see
Mechoulam & Hanus 2000 for review). Over 100 pCBs have
now been isolated from C. sativa (Elsohly & Slade 2005), but
despite their structural similarities, the pCBs show considerable
heterogeneity in their pharmacological targets and/or physiolog-
ical activities (Hill et al. 2012a).
One of the better known properties of C. sativa is its ability
to stimulate appetite (hyperphagia), which has been described
anecdotally by recreational users and demonstrated under lab-
oratory conditions (Hollister 1971; Mattes et al. 1994). In
rodent models, our laboratory has shown that oral administra-
tion of Δ9-THC to pre-satiated rats produced significant short-
term hyperphagia (Williams et al. 1998), characterised by a
marked reduction in latency to begin feeding (Williams and
Kirkham 2002a), an effect that was reversed by co-
administration of the selective CB1 receptor (CB1R) antago-
nist SR141716 (Williams and Kirkham 2002b). Similarly,
CB1R-mediated hyperphagic effects have also been observed
following administration of the endocannabinoids (eCB)
anandamide (AEA) (Williams & Kirkham 1999) and 2-
arachidonoylglyerol (2-AG) (Kirkham et al. 2002).
Importantly, in the latter study, we also demonstrated altered
brain levels of AEA and 2-AG during fasting and feeding
states, implicating eCBs in the control of appetite.
In the years since these findings, the role of the eCB system
in appetite regulation and energy balance has been the subject
of intensive research and is now emerging as a major target
area for a variety of metabolic disorders (see Di Marzo et al.
2011 for review). Despite promising therapeutic potential,
treatments directly targeting CB1R-mediated appetite regula-
tion have, thus far, had limited clinical success. The CB1R
antagonist SR141716 was licenced as an anti-obesity treat-
ment in Europe in 2006; however, it was withdrawn 2 years
later due to adverse side effects including depression and
suicidality (Derosa and Maffioli 2012). Synthetic Δ9-THC
(dronabinol) is licenced for treatment of chemotherapy-
induced nausea and vomiting; however, it is not recommend-
ed as a first-line treatment due to adverse side effects associ-
ated with its psychoactivity (Todaro 2012). Two clinical trials
conducted on Δ9-THC for appetite stimulation in cancer ca-
chexia patients did not show positive results, possibly due to
the low doses required to attain an acceptable tolerability pro-
file (Jatoi et al. 2002; Strasser et al. 2006).
Recently, we have started investigating the effects of the
non-Δ9-THC pCBs on feeding behaviour (Farrimond et al.
2010a; Farrimond et al. 2010b; Farrimond et al. 2012a;
Farrimond et al. 2012b; Brierley et al. 2016). This work sug-
gests that some pCBs may offer potential for therapeutic ap-
petite regulation without the psychoactive side effect profile of
Δ9-THC-containing preparations. In the present study, we
investigated the effects of one such pCB, cannabigerol
(CBG), which does not produce ‘cannabimimetic’ psychoac-
tive side effects and is hence typically described as non-
psychoactive (Mechoulam et al. 1970). CBG is a relatively
little-studied biosynthetic precursor (in C. sativa) of the major
pCBs Δ9-THC and cannabidiol (CBD) (Hill et al. 2012a).
Pharmacodynamic studies of CBG in vitro have determined
that i t acts as a potent α2-adrenoceptor agonist
(EC50 = 0.2 nM) and a modest 5-HT1AR competitive antago-
nist (at 10 μM) and can weakly bind, but not activate, CB1R
and CB2R (Ki = 81 and 2600 nM, respectively) (Cascio et al.
2010; Pertwee et al. 2010). Furthermore, it has been shown to
inhibit the reuptake of the endocannabinoid AEA
(IC50 = 11.3 μM) and interacts with a number of transient
receptor potential (TRP) channels, acting as an agonist at
TRPA1, TRPV1 and TRPV2 (EC50 = 0.7, 1.3 and 1.7 μM,
respectively) and as a potent antagonist at TRPM8
(IC50 = 0.16 μM) (De Petrocellis et al. 2011). CBG has also
recently been shown to block voltage-gated sodium channels
Nav 1.1, 1.2 and 1.5 (IC50 = 88, 79 and 36 μM, respectively)
(Hill et al. 2014). Given that CBG readily penetrates the blood
brain barrier (Deiana et al. 2012) and interacts with a number
of eCB and non-eCB targets with known involvement in the
control of feeding and energy balance (Halford et al. 2004; Di
Marzo and Matias 2005; Lee et al. 2015), the in vitro data
available suggest this that pCB could conceivably elicit a cen-
trally mediated stimulation of feeding behaviour. Although
there is a paucity of in vivo studies of CBG in general, and
feeding studies in particular, it has been reported that an acute
low dose (2.5 mg/kg, i.p.) administered to rats enhanced sac-
charin palatability in a taste reactivity test (O’Brien et al.
2013). As part of one of our previous studies, we investigated
the effects on feeding behaviour of low doses of CBG (0.176–
17.6 mg/kg, p.o.), which were scaled to the concentrations
found in a low-Δ9-THC cannabis extract which induced hy-
perphagia (Farrimond et al. 2012b). In that study however,
despite a suggestion of increased food intake over 2 h, no
significant effects of CBG on appetite were found.
The present study was thus conducted with the aim of in-
vestigating whether CBG was able to stimulate appetite, at
higher doses than previously tested. To ensure that any poten-
tial therapeutic utility of CBG would not be compromised by
detrimental neuromotor side effects, our first experiment com-
prised a neuromotor tolerability test battery to assess the
pCB’s effects on locomotor activity, balance, fine motor con-
trol and muscular strength. As CBG has previously been
found to have no cannabimimetic effects in the mouse tetrad
assay up to a maximal tested dose of 80 mg/kg (El-Alfy et al.
2010), had minimal behavioural effects (at 3–100 mg/kg) in a
mouse Irwin assay (Duncan et al. 2014) and no signs of acute
toxicity were reported in a pharmacokinetic study of 120-
mg/kg doses (Deiana et al. 2012), a dose range of 30–
120 mg/kg was used in this tolerability experiment.
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Subsequently, a second experiment was conducted using a
pre-feed satiation paradigm to assess the acute hyperphagic
effects of CBG. Results from a pilot of this experiment sug-
gested that CBG may elicit dose-dependent hyperphagia,
which did not appear to have a ceiling effect up to 120 mg/
kg, and so an additional 240-mg/kg dose group was included
in the design of the experiment. Infrared activity monitoring
was performed concurrently throughout the feeding experi-
ment to corroborate the effects of CBG on locomotor activity
determined during the tolerability battery and to extend this
investigation over a longer time frame and higher dose range.
Methods
Experiment 1: effects of CBG in a neuromotor tolerability
test battery
Drugs
CBG (GW Pharmaceuticals, UK) was dissolved directly into
sesame seed oil (by magnetic stirring at 57 °C) to produce a
maximal working concentration of 120 mg/ml. Working solu-
tions of 60 and 30 mg/ml were then prepared by serial dilu-
tion. CBG solutions were prepared freshly on each test day
and protected from light until administration.
Doses of CBG or sesame seed oil vehicle alone were ad-
ministered using a within-subject design, with all experimen-
tal units (individual animals) receiving 0, 30, 60 and 120 mg/
kg CBG according to a pseudo-random, counter balanced,
Latin square protocol. All animals received doses separated
by a minimum 48-h washout period. On test days, animals
were administered CBG or vehicle 60min prior to commence-
ment of testing. CBG or sesame seed oil vehicle was admin-
istered per ora (p.o.) via a syringe placed into the cheek pouch
at 1-ml/kg dosing volume.
Animals
Twelve young adult male Lister Hooded rats (Harlan, UK),
weighing 200–225 g on delivery, were housed in pairs in
temperature and humidity-controlled rooms with reversed
light cycles (dim red light 12:00–24:00), with standard labo-
ratory chow and water available ad libitum.
Procedure
Prior to testing, animals were subjected to a 5-day habituation
process, consisting of daily handling, vehicle drug administra-
tion, habituation to open field and static beam test procedures.
On test days, all procedures were conducted during the first
half of the dark period (12:00–18:00) in the same room as the
animals were housed. All test equipment was cleaned with
70% ethanol and allowed to dry completely between animals.
All tasks were presented in the order below with animals hav-
ing a 5-min rest period in their home cage between tasks.
Open field
Consisting of a 1.1 × 1.1 × 0.4-m black acrylic-lined box,
delineated into a 5 × 5 square grid and comprising a 3 × 3
central sector and a single square-wide peripheral sector, the
open field was illuminated by dim red light (∼10 lx). Animals
were placed in a consistent corner of the open field, and be-
haviour was video recorded for 5 min. Videos were analysed
offline using Observer XT software (Noldus, Netherlands).
Locomotor activity was quantified based on the number of
times animals crossed the lines on the open field floor, with
time spent in the central area of the field and latency to first
entry used to quantify anxiety-like behaviour (i.e. degree of
thigmotaxis). It should be noted that the habituation period
animals received to the open field component of the test bat-
tery is necessary for within-subject assessment of drug-
induced changes of locomotor activity. However, as a conse-
quence, the aversive/novel nature of the environment is atten-
uated in comparison to the non-habituated version of this task,
which is primarily used to assess anxiety-like behaviour.
Static beam
The apparatus consisted of a 3.2-cm-diameter cylindrical
beam, 1 m in length and suspended 0.5 m above floor level.
A bright light was positioned at the start of the beam and an
enclosed goal box at the end. Animals were placed at the start
of the beam and allowed a maximum of 5 min to successfully
traverse its length to reach the goal box. Animals were then
given a 2-min rest period in home cages prior to repeating the
test. Tests were video recorded for off-line coding using
Observer XT software (Noldus, Netherlands). In the static
beam test, performance generated four outcome measures,
based on successful completion or length of beam tra-
versed prior to falling (pass rate and distance travelled),
number of times paws were fully extended past the beam
(foot slips) and time taken to traverse the middle 50 cm of
beam (speed).
Forelimb grip strength
Animals completed two repeats of the forelimb grip
strength test, separated by a 30-s rest period. Animals were
placed with forelimbs gripping a trapeze bar connected to a
digital force gauge (FH50, Sauter GmbH, Germany), then
uniformly pulled by the tail base away from bar along the
horizontal plane until grip was released and peak force
recorded.
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Forelimb grip strength
Analysis All behavioural coding was conducted by an
experimenter blinded to treatment allocation. For static
beam and forelimb grip strength outcome measures,
where animals were subjected to two tests during the
battery, data represent the mean of the two technical
repeats, with the exception of pass rate on static beam
in which a score of 0–2 was allocated based on number
of successfully completed tests. All continuous data
were analysed using SPSS 18 (IBM, UK) by one-way
repeated measures ANOVA (ordinal pass rate data were
analysed by Friedman’s ANOVA), with degrees of free-
dom and p values corrected, where assumptions of
sphericity were violated (using Greenhouse-Geisser cor-
rection). When significant overall dose effects were ob-
served, planned comparisons of all dose groups vs ve-
hicle group were conducted to reveal any significant
pairwise comparisons. Results were considered signifi-
cant if p < 0.05.
Experiment 2: effects of CBG on feeding behaviour
Drugs
Briefly, on each test day, CBG (GW Pharmaceuticals, UK)
was dissolved in sesame seed oil and then serially diluted to
produce working solutions of 240, 120, 60 and 30 mg/ml.
Using a within-subject, counterbalanced, repeated measure
design, doses of CBG or vehicle were orally administered to
animals as described in experiment 1. Each test day was sep-
arated by a minimum 48-h washout.
Animals
Sixteen young adult male Lister Hooded rats (Harlan, UK),
weighing 200–225 g on delivery, were housed in pairs in
temperature and humidity-controlled rooms with reversed
light cycles (dim red light 12:00–24:00), with standard labo-
ratory chow and water available ad libitum.
Procedure
Acute feeding experiments were conducted in pre-satiated
animals using our well-established paradigm for the detec-
tion of hyperphagia following administration of cannabi-
noids (Williams et al. 1998). Additionally, concurrent mea-
surement of ambulatory activity and rearing during the
feeding test protocol was conducted, using two levels of
infrared photobeam activity sensors arrayed around the test
cages.
Prior to the start of testing, animals were habituated to
handling (10 days), vehicle dosing and the pre-feed procedure
(7 days) and the testing apparatus (5 days). The pre-feed pro-
cedure was conducted at the onset of the dark period, when
animals were transferred to individual cages containing
30.5 ± 0.5 g of highly palatable wet-mash food. The wet-
mash comprised 1-part rat and mouse expanded ground diet
(SDS, Witham, UK) and 1.25-part tap water. Animals were
allowed 2 h to consume the wet-mash, following which they
were returned to their home cages and quantity of wet-mash
consumedwas measured. Animals were habituated to this pre-
feed procedure until a stable consumption level was reached,
as indicated by a non-significant main effect of test day by
one-way ANOVA across four consecutive habituation days
(F3, 63 = 0.5603, p = 0.644), with mean consumption during
these days being 19.9–20.5 g.
On test days, immediately after the pre-feed procedure,
animals were administered doses of CBG or vehicle and
returned to their home cages for 1 h to allow for drug
assimilation, during which time food was unavailable.
Animals were then placed into feeder cages for 2 h, dur-
ing which time food consumption and locomotor activity
were recorded on automated food intake (TSE Systems,
Germany) and infrared photobeam activity systems (Ugo
Basile, Italy) and behaviour was video recorded. At the
end of the experiment, animals were returned to their
home cages, with food available ad libitum until the fol-
lowing test procedure ≥48 h later.
Quantity of food consumed during the 2 h test was
confirmed manually by weighing the remaining chow pel-
lets in the food hoppers and any crumbs in spillage trays
below the cages and subtracting these from the initial
weight of chow in the hopper. The automated food intake
system provided data output on the time, duration and size
of each feeding bout, which were confirmed from video
recordings as genuine feeding episodes as opposed to ex-
ploratory interactions with food hoppers. Feeding bouts
were combined into ‘meals’, defined as feeding bouts con-
suming ≥0.5 g and separated by ≥900 s, criteria previous-
ly shown to more accurately reflect the natural process of
food consumption (Williams & Kirkham 2002a; Farrimond
et al. 2012b).
Analysis
Data were analysed to provide measures of feeding behav-
iours during appetitive and consummatory phases, using the
parameters of latency to first meal and meal frequency
(appetitive) and meal sizes and durations (consummatory) in
addition to hourly and total intake quantities. Ambulatory lo-
comotor activity was quantified over the test duration using
the number of infrared beam breaks. All continuous data were
analysed using SPSS 18 (IBM, UK) by one-way repeated
measures ANOVA, with degrees of freedom and p values
corrected where assumptions of sphericity were violated
3606 Psychopharmacology (2016) 233:3603–3613
(using Greenhouse-Geisser correction). When significant
overall dose effects were observed, planned comparisons of
all dose groups vs vehicle group were conducted to reveal any
significant pairwise comparisons. Results were considered
significant if p < 0.05.
All experiments were performed at the University of
Reading in accordance with the principles of laboratory ani-
mal care, UK Home Office regulations [Animals (Scientific
Procedures) Act 1986] and the ARRIVE guidelines for
reporting experiments involving animals (Kilkenny et al.
2010; McGrath et al. 2010).
Results
Experiment 1: effect of CBG in a neuromotor tolerability
test battery
Open field test
General ambulatory activity in the open field test was not
modulated by administration of CBG at any dose (Table 1),
as determined by the number of line crosses observed (F3,
27 = 0.454, p = 0.716). Similarly, the lack of significant dose
effect on either duration spent in the central sector (F1.9,
17.6 = 1.80, p = 0.195) or the latency to enter the central sector
(F3, 27 = 0.262, p = 0.852) suggests that CBG does not have
any effect on anxiety-like behaviour in this version of the test.
Static beam test
CBG had no effect on any measure of balance or motor coor-
dination as assessed in the static beam test. Gross measures of
balance (Fig. 1a, b) were unaffected, as demonstrated by non-
significant effects of dose on pass rate (Fr3 = 3.667, p = 0.30)
and distance travelled (F1.5, 16.9 = 0.758, p = 0.451). Measures
of fine motor coordination (Fig. 2c, d) were similarly
unaffected, with non-significant effects of dose observed on
the number of foot slips (F1.5, 16.6 = 0.687, p = 0.477) and
speed across the beam (F3,33 = 0.699, p = 0.560).
Grip strength test
In the forelimb grip strength test for muscular strength and func-
tional neurotoxicity (Table 1), CBG also had no significant effect
on performance at any dose level (F3, 33 = 0.564, p = 0.643).
These data from the neuromotor tolerability test battery
extend the previous limited data in the literature to show that
acute oral doses of CBG up to 120 mg/kg do not elicit any
detrimental motoric side effects. On the basis of these find-
ings, we decided to conduct the feeding behaviour study
(Experiment 2) using the full dose range in Experiment 1
and an additional higher-dose group (240 mg/kg), with 2-h
ambulatory activity measured concurrently to corroborate
the open field data and assess if any sedative/motoric effect
was apparent at the highest dose level and/or over a longer test
duration.
Experiment 2: effect of CBG on feeding behaviour
Hourly food intake
The effectiveness of the pre-feed procedure was evident by the
very low baseline intake level in the vehicle group, which max-
imises the opportunity to detect drug-induced hyperphagia. The
total quantity of food consumed during the test period was
increased following CBG administration (Fig. 2a) in a dose-
dependent manner (F4, 60 = 3.967, p = 0.006). Overall, animals
consumed 1.66 (±0.37) g following 120 mg/kg and 1.89
(±0.38) g following 240 mg/kg CBG (F1, 15 = 5.328,
p = 0.036 and F1, 15 = 8.909, p = 0.009, respectively) compared
to 0.85 (±0.28) g for vehicle-treated animals. When broken
down by hourly consumption, a significant effect of CBG
was observed for hour 1 intake (F4, 60 = 2.607, p = 0.044);
Table 1 Behavioural parameters in the habituated open field and forelimb
grip strength test components of the neuromotor tolerability test
battery (Experiment 1). Administration of CBG at doses up to 120 mg/kg
had no deleterious effects on locomotor activity or grip strength performance
nor any effect on anxiety-like behaviours. Data presented asmean ± SEMand
analysed by one-way repeated measures ANOVA, all groups n = 12
CBG (mg/kg)
0 30 60 120
Open field test
Line crosses 136 (±18) 145 (±14) 142 (±6) 130 (±10)
Central sector duration (s) 23.1 (±4.7) 26.0 (±3.9) 33.1 (±5.9) 19.2 (±2.7)
Latency to central sector entry (s) 74.7 (±21.4) 70.2 (±24.3) 64.9 (±17.7) 85.9 (±20.7)
Grip strength test
Grip strength (kgf) 0.811 (±0.062) 0.747 (±0.044) 0.762 (±0.032) 0.740 (±0.051)
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however, no post hoc comparisons were significant, with only
the 120-mg/kg group nearing significance (F1, 15 = 3.741,
p = 0.072). In hour 2, a significant effect of CBG was observed
(F4, 60 = 2.722, p = 0.038), with vehicle-treated animals con-
suming 0.38 (±0.18) g, compared to 0.99 (±0.19) g following
240 mg/kg CBG (F1, 15 = 11.538, p = 0.004).
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Fig. 2 Total food intake and locomotor activity levels during the feeding
behaviour test (Experiment 2). Administration of CBG at 120 and
240 mg/kg increased food intake (a) and at 240 mg/kg increased
locomotor activity (b). Data presented as mean ± SEM and analysed by
one-way repeated measures ANOVA and planned comparisons. All
groups n = 16. *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 1 Performance parameters
in the static beam test component
of the neuromotor tolerability test
battery (Experiment 1).
Administration of CBG at doses
up to 120 mg/kg had no
deleterious effects on measures of
balance (a, b) or fine motor
control (c, d). Data presented as
mean ± SEM and analysed by
one-way repeated measures
ANOVA, all groups n = 12
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Fig. 3 Appetitive phase feeding behaviour parameters in the feeding
behaviour test (Experiment 2). Administration of CBG at 120 and
240 mg/kg increased the number of meals consumed (a) and at 240 mg/
kg reduced the latency to onset of feeding (b). Data presented as
mean ± SEM and analysed by one-way repeated measures ANOVA and
planned comparisons. All groups n = 16. *p < 0.05, **p < 0.01
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Analysis of meal microstucture
A more granular analysis of meal microstructure following
CBG administration revealed significant stimulatory effects
on feeding frequency and latency to feed (consistent with
appetitive stimulation), however only modest effects on
intra-meal factors consistent with consummatory stimulation
(Fig. 3 and Table 2). CBG treatment produced a significant
increase in the number of meals consumed during the test
(F4, 60 = 3.306, p = 0.016; Fig. 3a). On average, our pre-
feed procedure was so successful that vehicle-treated animals
consumed less than 1 meal (0.63 ± 0.20) during the test with
only 7/16 animals consuming any food at all and no animal
consuming more than 2 meals. In comparison, animals treated
with 120 and 240 mg/kg CBG consumed more than twice that
average number of meals (1.44 ± 0.33 [F1, 15 = 7.752,
p = 0.014] and 1.44 ± 0.29 [F1, 15 = 12.739, p = 0.003], re-
spectively), with 12/16 animals consuming at least 1 meal and
some consuming up to 4.
Given that most animals consumed two meals or fewer,
particularly in vehicle and low-dose CBG groups, we decided
to further investigate feeding behaviours during the consum-
matory phase by analysing the size and duration of the first
two meals consumed, both individually and cumulatively
(Table 2). A significant effect of CBG on the size of meal 1
was observed (F4, 60 = 2.630, p = 0.043); however, no signif-
icant comparisons were revealed. No significant effect of
CBG was observed on the size of meal 2 (F4, 60 = 2.124,
p = 0.089); however, a significant effect of CBGwas observed
on the cumulative size of these two meals (F4, 60 = 3.927,
p = 0.007). Whilst baseline intake in meals 1 + 2 was 0.85
(±0.28) g, animals administered 120 mg/kg CBG consumed
1.51 (±0.31) g (F1, 15 = 4.490, p = 0.051) and those adminis-
tered 240 mg/kg CBG consumed 1.68 (±0.34) g (F1,
15 = 6.951, p = 0.019) during these two meals. In contrast,
once feeding had started, the duration of feeding was not sig-
nificantly affected by CBG administration (see Table 2), with
no significant effect of CBG evident on the duration of meal 1
(F2.1, 31.6 = 1.628, p = 0.211) or meal 2 (F2.0, 30.0 = 1.827,
p = 0.178). A significant dose effect was observed on the
cumulative duration of these meals (F4, 60 = 2.626,
p = 0.043); however, no significant comparisons were re-
vealed. No significant effect of dose was observed on the total
duration of feeding (F2.4, 37.1 = 2.931, p = 0.055). To investi-
gate the appetitive aspect of feeding behaviour, we analysed
the latency to the onset of feeding (Fig. 3b), which was sig-
nificantly modulated by CBG (F4, 60 = 3.124, p = 0.021).
Administration of 240 mg/kg CBG reduced the latency to
feeding by approximately 30 min compared with vehicle-
treated animals (F1,15 = 7.285, p = 0.016), for which the mean
feeding onset was at ∼80 min. Whilst similar patterns were
seen with the 120-mg/kg dose, no significant effect was seen
(F1,15 = 3.651, p = 0.075).
Overall, these data from experiment 2 demonstrate that
administration of CBG at 120–240 mg/kg elicits hyperphagia
even under conditions designed to minimise food intake. This
Table 2 Hourly food intake and meal pattern microstructure parameters in the feeding behaviour test (Experiment 2)
CBG (mg/kg)
0 30 60 120 240
Hourly food intake (g)
Hour 1 0.47 (±0.22) 0.40 (±0.25) 0.55 (±0.25) 1.06 (±0.30) 0.89 (±0.25)
Hour 2 0.38 (±0.18) 0.49 (±0.20) 0.46 (±0.17) 0.59 (±0.15) 0.99** (±0.19)
Total 0.85 (±0.28) 0.89 (±0.40) 1.01 (±0.29) 1.66* (±0.37) 1.89** (±0.38)
Meal size (g)
Meal 1 0.65 (±0.23) 0.38 (±0.16) 0.57 (±0.19) 0.93 (±0.18) 1.04 (±0.23)
Meal 2 0.20 (±0.11) 0.30 (±0.15) 0.22 (±0.09) 0.57 (±0.23) 0.64 (±0.18)
Meal 1 + 2 0.85 (±0.28) 0.68 (±0.30) 0.79 (±0.24) 1.51 (±0.31) 1.68* (±0.34)
Meal duration (min)
Meal 1 5.9 (±2.7) 1.1 (±0.7) 3.1 (±1.2) 4.0 (±1.1) 5.9 (±1.9)
Meal 2 0.3 (±0.2) 0.8 (±0.5) 0.5 (±0.3) 2.4 (±1.5) 2.9 (±1.1)
Meal 1 + 2 6.2 (±2.7) 1.9 (±1.1) 3.6 (±1.3) 6.4 (±1.8) 8.7 (±2.3)
All meals 6.2 (±2.7) 3.0 (±1.5) 3.6 (±1.3) 8.7 (±2.7) 9.1 (±2.3)
Following administration of 240 mg/kg CBG, hour 2 and total food intake were increased, as was the size of meal 1 + 2. Total consumption was also
increased following administration of 120 mg/kg CBG. Data presented as mean ± SEM and analysed by one-way repeated measures ANOVA and
planned comparisons. All groups n = 16
*p < 0.05
**p < 0.01
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dose-dependent hyperphagia was primarily driven by stimu-
lation of behaviours during the appetitive phase, causing ani-
mals to begin feeding sooner and eat more meals, resulting in
greater overall food intake during the test period.
Hourly locomotor activity
To corroborate and extend the investigation of the effects of
CBG on general locomotor activity in Experiment 1, we con-
currently measured ambulatory and rearing behaviour in the
feeding test cages throughout the duration of Experiment 2 to
establish the effects of CBG over an extended time period and
greater dose range. Whilst the absence of any detrimental
sedative effect of CBG (up to 120 mg/kg) from the open field
test was confirmed, interestingly, CBG in fact produced a
significant stimulant effect on locomotor activity over the 2-
h duration of the feeding test (Fig. 2b). The significant dose
effect of CBG (F4, 60 = 7.121, p < 0.0005) was due to an
almost 50% increase in ambulatory activity in animals admin-
istered 240 mg/kg CBG (F1, 15 = 58.325, p < 0.0005), al-
though activity in animals administered 30–120-mg/kg doses
was not significantly increased. CBG administration did not
have any effect on exploratory rearing behaviour over the 2-h
test duration (F2.3, 33.8 = 2.853, p = 0.066).
Discussion
The data presented here demonstrate a novel activity of CBG,
as an appetite stimulant at 120–240 mg/kg. At these doses,
CBG increased food intake, predominantly via stimulation of
appetitive phase feeding behaviours. Furthermore, CBG
acutely administered at doses ≤120 mg/kg did not elicit any
detrimental neuromotor effects on locomotor activity, balance,
fine motor control or muscular strength, and at 240 mg/kg
appears to have some stimulant activity.
The widely utilised and validated feeding paradigm
employed in this study is designed to sensitively detect even
relatively small hyperphagic actions of cannabinoid agents
(Williams et al. 1998). The paradigm provides detailed anal-
ysis of meal microstructure, allowing quantification of dis-
crete behaviours during the appetitive and consummatory
phases of feeding. The incorporation of an infrared locomotor
activity monitoring system provides additional measures of
ambulatory activity and rearing behaviour, allowing differen-
tiation of locomotion-dependent and locomotion-independent
effects of drugs on feeding behaviour. The use of this para-
digm in the present study allows the direct comparison of the
effects of CBG to previously published results using the same
paradigm for the eCB anandamide (Williams and Kirkham
2002a); the purified pCBs Δ9-THC, CBD, cannabiniol
(CBN) and cannabidiolic acid (Williams et al. 1998;
Williams and Kirkham 2002b; Williams and Kirkham
2002a; Farrimond et al. 2012b; Brierley et al. 2016); and
low- and non-Δ9-THC cannabis extracts and analogues
(Farrimond et al. 2010a; Farrimond et al. 2010b; Farrimond
et al. 2012a). It should be noted that, unlike these previous
studies ofΔ9-THC, the doses of CBG used in the present study
are considerably higher than concentrations typically found in
whole C. sativa preparations. As such, the hyperphagic activ-
ity of CBG reported here is unlikely to meaningfully contrib-
ute to the appetite-stimulating effects of cannabis consump-
tion in humans.
In this study, administration of CBG at 120–240 mg/kg
dose dependently increased total food intake over the 2-h test
period. This is in contrast to previous studies of various Δ9-
THC formulations, which elicit a robust increase in intake
during hour 1 followed by a compensatory decrease during
hour 2 (Farrimond et al. 2010a; Farrimond et al. 2012a). The
pCB CBN elicits a similar biphasic effect on food intake dur-
ing this 2-h paradigm, with hyperphagia blocked by the CB1R
antagonist SR141716, indicative of a Δ9-THC-like mecha-
nism of action (Farrimond et al. 2012b). In our study, CBG
also increased appetitive phase feeding behaviour, with the
onset of feeding advanced by approximately 30 min, from
83 to 54 min. However, this is somewhat in contrast to previ-
ous studies of Δ9-THC formulations and CBN, in which feed-
ing was initiated within 10–20 min, despite similar long laten-
cies in vehicle groups (Farrimond et al. 2010a; Farrimond
et al. 2012a; Farrimond et al. 2012b). Hence, it appears that
whilst CBG may stimulate the appetitive component of feed-
ing behaviour, it does so to a lesser degree than Δ9-THC and
CBN.
Whilst the CBG-induced increase in feeding frequency and
decrease in latency are consistent with stimulation of the ap-
petitive component of feeding, the modest effects on intra-
meal factors provide little evidence for stimulation of the con-
summatory component. Given that a significant effect of CBG
was only evident on the cumulative size of meals 1 and 2, it is
apparent that increased consumption is predominantly driven
by the dose-dependent increase in feeding frequency, rather
than significant increase in individual meal sizes. Similarly,
the lack of significantly increased durations of individual
meals does not support a stimulatory effect of CBG on the
consummatory component of feeding behaviour. Differences
are thus again evident between consummatory meal micro-
structure parameters following administration of CBG, and
those of Δ9-THC formulations, which are typified by robust
increases in both the size and duration of the first meal con-
sumed (Farrimond et al. 2010a). Considered overall, the alter-
ations in food intake and meal pattern microstructure induced
by CBG demonstrate a dose-dependent hyperphagic effect,
predominantly mediated by stimulation of the appetitive com-
ponent of feeding behaviour.
Such differences in patterns of feeding behaviour stimula-
tion between CBG and pCBs acting directly as CB1R agonists
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are consistent with the limited in vitro pharmacodynamic data
on CBG, which have shown that whilst it has some affinity for
this receptor, it does not appear to activate it (Cascio et al.
2010; Pertwee et al. 2010). Given that CBG has been shown
to be one of the most effective pCBs at inhibiting AEA reup-
take (De Petrocellis et al. 2011), it is instead possible that it
elicits CB1R-mediated hyperphagia in an indirect manner, via
upregulation of orexigenic endocannabinoid tone (Kirkham
et al. 2002; Reyes-Cabello et al. 2012). The TRPV1 agonist
activity of CBG could conceivably contribute to such a mech-
anism, given the recent observation that TRPV1 agonists can
themselves inhibit AEA reuptake (Hofmann et al. 2014).
Alternatively, CBG-induced hyperphagia may be mediated
by its activity (to date only observed in vitro) as a highly
potent agonist of α2-adrenoceptors (Cascio et al. 2010).
Consistent with this, stimulation of α2-adrenoceptors in the
hypothalamic paraventricular nucleus has been shown to have
hyperphagic effects in satiated rats (Wellman et al. 1993;
Taksande et al. 2011), whilst administration of the α2-
adrenoceptor agonist clonidine into the median raphe nucleus
had orexigenic effects in free feeding (Mansur et al. 2010) but
not fasted or food-restricted rats (Ribas et al. 2012). Whilst the
above studies suggest that central α2-adrenoceptor activation
may be involved in the hyperphagic activity of CBG, it should
be noted that recent cardiovascular safety assays in dog did
not reveal any effects on cardiovascular parameters (T. Hill,
personal communication), indicating that α2-adrenoceptor
agonism may not be the predominant action for CBG. Given
that cannabinoids acting as CB1R agonists have demonstrated
limited clinical utility as appetite stimulants, the possibility
that CBG induces hyperphagia via indirect and/or CB1R-in-
dependent mechanisms warrants urgent further investigation,
as this pCB may represent a valuable novel therapeutic option
for such applications.
A further interesting observation from the feeding experi-
ment is the stimulation of ambulatory activity over the 2-h test
duration. These data support the predicted lack of sedative
effect for the 240 mg/kg dose based on results up to 120 mg/
kg in the neuromotor test battery. However, they are not whol-
ly consistent, given that a non-significant increase in activity
during the feeding experiment was observed at 120 mg/kg,
which was not observed in the open field test. This is not
inherently contradictory however, as it is plausible that differ-
ences in test environment, and the considerably longer test
duration and drug exposure time (180 vs 65 min from drug
administration), allow the detection of effects too subtle to be
observed in the open field.
The coincident increases in total food intake and ambu-
latory activity suggest the following two possible alterna-
tive interpretations of these data: that increased locomotor
activity is an artefact of increased food seeking; or that
increased food intake is secondary to increased activity or
general arousal. For the first interpretation to be valid, any
compound which increases food intake by a similar mag-
nitude in this system would have to also increase locomo-
tor activity levels. However, validation studies of the feed-
ing and activity cages, using 0.5–2-mg/kg Δ9-THC-con-
taining formulations, resulted in the expected stimulation
of feeding behaviours but did not increase locomotor ac-
tivity (unpublished observations). Given these data, and
video observations showing that the majority of animals’
activities in the cages were exploratory rather than food
seeking, it is apparent that the activity data do indeed
represent generalised locomotor stimulation. For this loco-
motor stimulation to be the primary driver of increased
food intake, via a general arousal mechanism, patterns of
activity and food intake would have to closely mirror one
another, both in terms of temporal profile and dose re-
sponse. Upon close inspection of hourly intake and activ-
ity levels, it can be observed that whilst intake levels in
hour 2 are very similar to hour 1 (and indeed 10 % higher
in the 240-mg/kg group), activity levels in hour 2 are
approximately half that in hour 1(data not shown).
Further evidence of the disconnect between activity and
intake can been seen in the dose response, with the
highest intakes during hour 1 in the 120 mg/kg group,
in contrast to the highest activity levels being in the 240
mg/kg group. These data thus argue against the interpre-
tation that the hyperphagic activity of CBG is driven by
generalised arousal, but rather that this compound directly
stimulates motivation to feed, with coincident feeding-
independent locomotor activation apparent at the highest
dose. Whilst beyond the scope of the present study, this
apparent stimulant effect of higher CBG doses warrants
further investigation in models which can assess locomotor
activation over extended time periods, without any con-
founding effects of feeding stimulation.
The tests comprising the neuromotor tolerability bat-
tery have been previously utilised for the assessment of
pCBs and other drugs with known clinical neuromotor
side effects. A number of drugs with known sedative
effects in humans, e.g. Δ9-THC and benzodiazepines,
elicit a sedative effect on locomotor activity in the open
field test (Navarro et al. 1993; Prut and Belzung 2003).
The static beam and grip strength tests have similar
predictive validity for clinically observed detrimental
motor effects, with both the anti-epileptic drug valproate
and Δ9-THC-containing cannabis extracts resulting in
impaired performance in these tests (Hill et al. 2012b,
2013). In contrast to Δ9-THC, but like the non-
psychoactive pCBs CBD and cannabidiolic acid (Long
et al. 2010; Brierley et al. 2016), CBG in the present
study had no effect at any dose on locomotor activity in
the open field test. In the static beam and grip strength
tests, CBG did not elicit any detrimental effect on bal-
ance or fine motor control measures, nor on muscular
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strength, again in contrast to previous reports of the
effects of Δ9-THC-containing cannabis extracts in these
tests (Hill et al. 2013). To the best of our knowledge,
the only published investigation of the side effect pro-
file of CBG has been in the mouse tetrad test for classic
cannabimimetic activity, in which it did not induce typ-
ical CB1R-mediated effects of hypomotility, catalepsy,
hypothermia or analgesia up to the maximal tested dose
of 80 mg/kg (El-Alfy et al. 2010). The present study
thus confirms that acute CBG administration does not
elicit sedation and further demonstrates that it does not
have detrimental effects on balance, motor control or
muscular strength.
Conclusion
The present study demonstrates for the first time that the
non-psychoactive plant cannabinoid CBG is able to stim-
ulate appetite in pre-satiated rats, and does so without
detrimental neuromotor side effects. Analysis of meal pat-
tern microstructure revealed that CBG predominantly stim-
ulated feeding behaviour by decreasing the latency to feed
and increasing the frequency of feeding rather than by
increasing individual meal size or duration. This observed
meal pattern is distinct from that elicited by the major
psychoactive plant cannabinoid Δ9-THC, suggesting that
CBG acts via an as yet undetermined mechanism unlikely
to be direct activation of CB1R. These data thus provide a
rationale for pre-clinical investigation of CBG as a novel
treatment in models of cancer- or chemotherapy-induced
cachexia, for which there is an urgent unmet clinical need
for well-tolerated appetite stimulants.
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